89bio (ETNB) Forward PE Ratio : 0.00 (As of May. 31, 2024)

View and export this data going back to 2019. Start your Free Trial

What is 89bio Forward PE Ratio?

89bio's Forward PE Ratio for today is 0.00.

89bio's PE Ratio without NRI for today is 0.00.

89bio's PE Ratio for today is 0.00.

89bio Forward PE Ratio Historical Data

The historical data trend for 89bio's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

89bio Forward PE Ratio Chart

89bio Annual Data

Trend

Forward PE Ratio

89bio Quarterly Data

Forward PE Ratio

Competitive Comparison of 89bio's Forward PE Ratio

For the Biotechnology subindustry, 89bio's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

89bio's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 89bio's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where 89bio's Forward PE Ratio falls into.

89bio Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

89bio (NAS:ETNB) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

89bio Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of 89bio's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

89bio (ETNB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 89bio Inc (NAS:ETNB) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

142 Sansome Street, Second Floor, San Francisco, CA, USA, 94104

Website

https://www.89bio.com

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Executives

Kathleen Laporte	director
Rohan Palekar	director, officer: Chief Executive Officer	201 SPEAR STREET, THIRD FLOOR, SAN FRANCISCO CA 94105
Atkinson Edward Morrow Iii	director	C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Quoc Le-nguyen	officer: See Remarks	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Ryan Martins	officer: Chief Financial Officer	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Michael R Hayden	director	C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ram Waisbourd	officer: See Remarks	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Gregory Grunberg	director, 10 percent owner	100 BEAVER STREET, WALTHAM MA 02453
Anat Naschitz	director, 10 percent owner	535 MISSION STREET, 14TH FLOOR, SAN FRANCISCO CA 94105
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026